Dermira to Present at Evercore ISI HealthCONx Conference
November 19 2018 - 8:00AM
Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated
to bringing biotech ingenuity to medical dermatology by delivering
differentiated, new therapies to the millions of patients living
with chronic skin conditions, today announced that company
management will participate in a fireside chat at the Evercore ISI
HealthCONx Conference.
- Location: Boston, MA
- Presentation date: Tuesday November 27, 2018
- Presentation time: 2:00 p.m. ET
A live audio webcast and archive of the
presentation will be available at http://investor.dermira.com.
About Dermira
Dermira is a biopharmaceutical company
dedicated to bringing biotech ingenuity to medical dermatology by
delivering differentiated, new therapies to the millions of
patients living with chronic skin conditions. Dermira is
committed to understanding the needs of both patients and
physicians and using its insight to identify, develop and
commercialize leading-edge medical dermatology programs. The
company’s approved treatment, QBREXZA™ (glycopyrronium) cloth, is
indicated for pediatric and adult patients (ages nine and older)
with primary axillary hyperhidrosis (excessive underarm sweating).
Dermira is also evaluating lebrikizumab in a Phase 2b clinical
trial for the treatment of moderate-to-severe atopic dermatitis (a
severe form of eczema) and has early-stage research programs in
other areas of dermatology. Dermira is headquartered
in Menlo Park, Calif. For more information, please visit
http://www.dermira.com. Follow Dermira on Twitter, LinkedIn
and Instagram.
In addition to filings with the Securities
and Exchange Commission (SEC), press releases, public
conference calls and webcasts, Dermira uses its website
(www.dermira.com), LinkedIn page
(https://www.linkedin.com/company/dermira-inc-), corporate
Instagram account (https://www.instagram.com/dermira_inc/) and
corporate Twitter account (@DermiraInc) as channels of distribution
of information about its company, product candidates, planned
financial and other announcements, attendance at upcoming investor
and industry conferences and other matters. Such information may be
deemed material information and Dermira may use these
channels to comply with its disclosure obligations under Regulation
FD. Therefore, investors should monitor Dermira’s website, LinkedIn
page, Instagram and Twitter accounts in addition to following
its SEC filings, news releases, public conference calls
and webcasts.
Contacts:
Media:
Erica JeffersonVice President, Corporate
Communications650-421-7216erica.jefferson@dermira.com
Investors:
Ian Clements, Ph.D.Vice President, Investor
Relations650-422-7753investor@dermira.com
Journey Medical (NASDAQ:DERM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Journey Medical (NASDAQ:DERM)
Historical Stock Chart
From Jul 2023 to Jul 2024